NCT03292536终止1 期
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Change in urinary N-telopeptide level
研究概览
简要总结
This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •At least 1 bone metastases must be present
- •Urinary N-telopeptide level above 20nM BCE/mM creatinine measured at ARUP
- •Archived or freshly biopsied primary and/or bone metastatic tumor tissue available in paraffin-embedded blocks or slides that is expected to yield 9 slides
- •Life expectancy of ≥ 6 months
- •Toxicity related to prior treatments must either have resolved to grade 1 or less, returned to baseline, or be deemed irreversible
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 28 days prior to enrollment)
- •Planning to remain on current breast cancer therapy for at least 12 weeks.
- •At least one prior line of therapy for metastatic breast cancer
- •Concurrent treatment with bisphosphonates or denosumab is required.
排除标准
- •Unable to swallow or take anything orally
- •ECG abnormalities:
- •Prolonged QTcF (Fredericia's correction) interval on screening ECG (≥ 450 msec)
- •QRS ˃ 120 msec
- •PR ˃ 210 msec
- •Any prior history, or current evidence of second- or third-degree heart block
- •Heart rate ˂ 40 beats per minute at screening
- •ECG second degree heart block (Mobitz's Type 2 or Wenckebach)
- •Complete heart block
- •Left bundle branch block or bifascicular block (right bundle branch block and left anterior hemiblock together)
- •Episodes of ventricular tachycardia
- •Any known prior malignancy (not including non-melanoma skin cancers), unless treated with curative intent
- •A serious uncontrolled medical disorder or active infection, which would impair the ability of the subject to receive protocol therapy
- •Current or recent (within 3 months) gastrointestinal disease that could impact the absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening)
- •Inadequate bone marrow function defined as:
- •Absolute neutrophil count (ANC) ˂ 1,500 cells/mm3
- •Platelet count ˂ 100,000 cells/mm3
- •Hemoglobin ˂ 9 g/dL
- •Inadequate hepatic function defined as:
- •Total bilirubin ˃ 1.5 x institutional upper limit of normal (IULN) (Unless due to diagnosis of Gilbert's Syndrome)
- •Alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) ˃ 2.5 x IULN
- •Inadequate renal function defined as: Serum creatinine ˃ 1.5 x ULN
- •Prothrombin time (PT)/partial thromboplastin time (PTT) ˃ 1.5 times the ULN
- •Serum sodium, potassium, and calcium levels not within normal limits.
- •Any atrophic macular condition including intermediate or advanced age-related macular degeneration
- •Patients receiving medications that are known to be substrates of CYP2C8 (including paclitaxel), CYP2C9, or CYP2C19 or to be oral substrates of CYP3A with narrow therapeutic window (listed on http://medicine.iupui.edu/clinpharm/ddis/main-table). Subjects who have discontinued any of these medications must have a wash-out period of at least 5 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of merestinib
- •Exposure to any investigational drug or placebo within 4 weeks of enrollment
- •Any other sound medical, psychiatric, and/or social reasons as determined by the investigator
- •History of diseases with influence on bone metabolism, such as Paget's disease, osteogenesis imperfecta, active primary or secondary hyperparathyroidism, and primary or secondary hyperthyroidism within 12 months prior to study entry
- •Patients with known symptomatic brain metastasis. Subjects with controlled brain metastasis (no radiographic progression at least 4 weeks following radiation and/or surgical treatment and no neurological signs or symptoms) will be allowed
- •History of allergy to merestinib or chemically related compounds
- •History of osteonecrosis of the jaw
- •Change in chemotherapy or hormone therapy within 8 weeks of the start of the study.
- •Active gout or inflammatory arthritis requiring treatment
- •Use within 28 days of registration of calcitonin, recombinant parathyroid hormone-related peptides, mithramycin, radium, strontium ranelate, or gallium nitrate.
- •Adult patients who require monitored anesthesia for PET scanning due to claustrophobia.
研究组 & 干预措施
Merestinib, all patients
Experimental
干预措施: Merestinib (Drug)
结局指标
主要结局
Change in urinary N-telopeptide level
时间窗: 12 weeks
To measure the change in urinary N-telopeptide level after 12 weeks of therapy with merestinib
Adverse Events that Occur
时间窗: 12 weeks, checked at every visit in that time period
To assess the tolerability of merestinib in combination with standard breast cancer therapies.
次要结局
- Time to skeletal-related events(12 weeks)
- Absolute and percentage change in serum B-CTX, TRAP-5b, P1NP and BSAP(12 weeks)
- Change in pain scores(12 weeks)
- Change in pain by narcotic use(12 weeks)
- Change in bone lesion uptake(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian CancersWith MSS/pMMR Advanced, Platinum-resistant Ovarian CancerNCT06513624National University Hospital, Singapore16
招募中
1 期
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid LeukemiaAML With Gene MutationsNCT06366789Lomond Therapeutics Holdings, Inc.150
招募中
1 期
Phase I/II Study of IPG1094 in Advanced Solid Tumors PatientsSolid TumorNCT06212076Nanjing Immunophage Biotech Co., Ltd60
Unknown
1 期
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell LymphomaB-cell Non-Hodgkin LymphomaNCT04296461UWELL Biopharma20
已完成
1 期
Safety of TKI258 in Advanced/Metastatic Melanoma SubjectsMelanomaNCT00303251Novartis Pharmaceuticals47